



213208

00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: Patient ID: Patient Group No:			_ Date: _ Patient Date Of Birth:		8/12/2024 Physician Name: Specialty: Physician Office Telephone:				
		NPI#:	Patient Phone:	Spe					
Phy	ysician Office Address:						<u>-</u>		
Drug Name (specify drug)									
Qua	antity:	Frequency:	Streng						
			Expected Length of Therapy:						
			_ ICD Code:						
Cor									
	• • •	te answer for each applical	ble question.						
1.	What is the patient's dia	•							
	Active systemic lupus	erythematosus (SLE) (If che	ecked, go to 2)		Ш				
	Active lupus nephritis	(If checked, go to 2)							
	Other, please specify	. (If checked, no further ques	ations)						
2.	Is the patient currently re	eceiving treatment with the re	equested medication?	Υ		N			
3.	disease activity or impro REQUIRED: If Yes, atta disease stability or impro	evement in signs and sympto ch medical records (e.g., cha	nical response as evidenced by low ms of the condition? ACTION art notes, lab reports) documenting ntation	Y		N			
4.	Will the patient be using	the requested drug in comb	ination with other biologics?	Υ		N			
5.	seizures that are attribut	ted to CNS lupus, psychosis.	system (CNS) lupus [including , organic brain syndrome, cerebritis, ore initiation of the requested drug]?	or Y		N			
6.	Will the patient be using	the requested drug in comb	ination with other biologics?	Y		N			
7.	What is the patient's dia	•							
	Active systemic lupus	erythematosus (SLE) (If che	ecked, go to 8)		Ш				
	Active lupus nephritis	(If checked, go to 10)							
8.	lupus erythematosus (S complement proteins)? notes, lab reports) docu	LE) (e.g., ANA, anti-ds DNA, ACTION REQUIRED: If Yes,	utoantibodies relevant to systemic anti-Sm, antiphospholipid antibodie attach medical records (e.g., chart pantibodies relevant to SLE (e.g., dies, complement proteins).	es,					
	Yes (If checked, go to	9)							
	No (If checked, no fur	ther questions)							
	Unknown (If checked,	, no further questions)							
	ACTION REQUIRED:	Submit supporting documer	ntation						

9.	Is the patient currently receiving a stable standard treatment regimen for systemic lupus erythematosus (SLE) with any of the following (alone or in combination)?							
	Yes, glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone) (If checked, no further questions)							
	Yes, antimalarials (e.g., hydroxychloroquine) (If checked, no further questions)							
	Yes, immunosuppressives (e.g., azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide) (If checked, no further questions)							
	Yes, nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., ibuprofen, naproxen) (If checked, no further questions)							
	No (If checked, no further questions)							
10.	Prior to initiating therapy, is the patient positive for autoantibodies relevant to systemic lupus erythematosus (SLE) (e.g., ANA, anti-ds DNA, anti-Sm, antiphospholipid antibodies, complement proteins) or was lupus nephritis confirmed on kidney biopsy? ACTION REQUIRED: If Yes, attach medical records (e.g., chart notes, lab reports) documenting the presence of autoantibodies relevant to SLE (e.g., ANA, anti-ds DNA, anti-Sm, antiphospholipid antibodies, complement proteins) or kidney biopsy confirming diagnosis.							
	Yes (If checked, go to 11)							
	No (If checked, no further questions)							
	Unknown (If checked, no further questions)							
	ACTION REQUIRED: Submit supporting documentation							
11.	Is the patient currently receiving a stable standard therapy regimen for lupus nephritis (e.g., cyclophosphamide, mycophenolate mofetil, azathioprine, glucocorticoids)?	Y		N				
I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.								

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.